Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

For Residents, Mystery Patients Often Require Rheumatologist Advice

Veena S. Katikineni, MD  |  September 20, 2018

As a first-year internal medicine resident, I find myself consulting rheumatologists for just about every mystery patient in our hospital. Like many residents, I was initially intimidated by the complexity of this elusive field. At first glance, diagnosis and management seem completely inaccessible to a first-year resident. But several rheumatology consults later, I can confidently…

Filed under:Education & TrainingProfessional Topics Tagged with:Educationlearning toolsresidentsTraining

The 2018 ACR/ARHP Annual Meeting Program Preview

From the College  |  September 20, 2018

Save the date for the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Connect with your colleagues for an unmatched educational experience featuring exceptional sessions by leading rheumatology experts. The ACR/ARHP Annual Meeting is your gateway to global rheumatology education. With more than 450 sessions—including The Great Debate—the meeting provides boundless opportunities for professional development,…

Filed under:From the College Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)

HCQ Debate: Should Dose Be No More Than 5 mg/kg in All SLE Patients?

From the College  |  September 20, 2018

Multiple studies show that hydroxychloroquine (HCQ) has many benefits in systemic lupus erythematosus (SLE), including cardiovascular benefits, such as reducing coronary artery and thrombosis risks. HCQ can prevent disease flares, including in renal and central nervous system lupus, and is the only drug shown to prolong survival in lupus. However, guidelines released in 2016 by…

Filed under:From the CollegeSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingdosageHCQHYDROXYCHLOROQUINE

Sessions to Check Out During the 2018 ACR/ARHP Annual Meeting

From the College  |  September 17, 2018

With more than 450 sessions, the 2018 ACR/ARHP Annual Meeting, is your gateway to global rheumatology education. Here is a preview of a few sessions attendees can look forward to…

Filed under:Conditions Tagged with:2018 ACR/ARHP Annual MeetingACR/ARHP Annual Meeting

Delayed Care: Research Paints Complex Picture of Treatment Delays

Thomas R. Collins  |  September 11, 2018

AMSTERDAM—A variety of factors lead to delays in patients seeking medical care for rheumatoid arthritis—from the nature of symptoms to coping tendencies—requiring more awareness from physicians when managing patients, researchers said at EULAR: the Annual European Congress of Rheumatology. Longer delays in treatment bring about more emotional distress to patients, missed chances to ease symptoms…

Filed under:ConditionsEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:delayed careEULAREuropepatientRheumatoid Arthritis (RA)

Promote Pregnancy Wellness: Data Can Help Guide Pregnancy Management in Lupus

Thomas R. Collins  |  September 10, 2018

AMSTERDAM—Clinicians who are counseling women with systemic lupus erythematosus (SLE) have the benefit of an array of new insights into factors linked with increased risk of pregnancy loss, how SLE therapies affect pregnancy and data on outcomes of children born to mothers with SLE, an expert said in a session at EULAR: the Annual European…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:HYDROXYCHLOROQUINELupus nephritispregnancypregnant womensystemic lupus erythematosus (SLE)

Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE

Lara C. Pullen, PhD  |  September 6, 2018

A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:baricitiniborgan damagerashsystemic lupus erythematosus (SLE)

Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

Lorraine L. Janeczko  |  August 20, 2018

NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it. “The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with…

Filed under:Axial SpondyloarthritisConditions Tagged with:adalimumabaxial spondyloarthritis (SpA)non-radiographic axial spondyloarthritisRemission

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

Thomas R. Collins  |  August 17, 2018

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabbiosimilar substitutionsEnbreletanerceptHumiraINFLECTRA (infliximabdyyb)REMICADE (infliximab)Rituxanrituximab

Atacicept Shows Promise in Lupus Treatment Trials

Mary Beth Nierengarten  |  August 17, 2018

A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the…

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:atacicept

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 68
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences